Download presentation
Presentation is loading. Please wait.
Published byΕφροσύνη Παπανδρέου Modified over 6 years ago
1
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study by Guillaume Cartron, Sophie de Guibert, Marie-Sarah Dilhuydy, Franck Morschhauser, Veronique Leblond, Jehan Dupuis, Beatrice Mahe, Reda Bouabdallah, Guiyuan Lei, Michael Wenger, Elisabeth Wassner-Fritsch, and Michael Hallek Blood Volume 124(14): October 2, 2014 ©2014 by American Society of Hematology
2
Study design and patient disposition in the GAUGUIN study.
Study design and patient disposition in the GAUGUIN study. (A) Phase 1. (B) Phase 2. *One patient enrolled in phase 2 of GAUGUIN did not enter follow-up because of a new anti-leukemia therapy. Guillaume Cartron et al. Blood 2014;124: ©2014 by American Society of Hematology
3
Complement and cytokine levels over time among phase 1 and 2 study participants.
Complement and cytokine levels over time among phase 1 and 2 study participants. (A) Complement C3 and C4 (mean ± standard deviation). (B) Cytokines (mean ± standard deviation). C, cycle; D, day. Guillaume Cartron et al. Blood 2014;124: ©2014 by American Society of Hematology
4
Kaplan-Meier plot of PFS in phase 2 of the GAUGUIN study.
Guillaume Cartron et al. Blood 2014;124: ©2014 by American Society of Hematology
5
ETR by baseline tumor burden in phase 1 and 2 of the GAUGUIN study
ETR by baseline tumor burden in phase 1 and 2 of the GAUGUIN study. *In phase 1 of GAUGUIN, 4 different doses of obinutuzumab were evaluated. ETR by baseline tumor burden in phase 1 and 2 of the GAUGUIN study. *In phase 1 of GAUGUIN, 4 different doses of obinutuzumab were evaluated. In phase 2, all patients received obinutuzumab 1000/1000 mg. The size of the bar below the x-axis reflects the dose received by the patient. Guillaume Cartron et al. Blood 2014;124: ©2014 by American Society of Hematology
6
Pharmacokinetic and pharmacodynamic properties of obinutuzumab.
Pharmacokinetic and pharmacodynamic properties of obinutuzumab. (A) Mean serum concentrations of obinutuzumab over time. (B) B-lymphocyte count over time in all GAUGUIN study participants. Reported lymphocyte counts are preinfusion for each. FU, follow-up; SD, standard deviation; W, week. The 2 patients who were B-cell depleted at screening were included based on prior CLL diagnoses and lymph node progression. Guillaume Cartron et al. Blood 2014;124: ©2014 by American Society of Hematology
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.